In a phase II clinical trial, a combination of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor (G-CSF)) regimen and imatinib mesylate was investigated in patients with R/R AML. Here, CSF3 is linked to acute myeloid leukemia.